Stocktoria
Cellectar Biosciences, Inc. CLRB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2005-05-20
Cellectar Biosciences, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $11.5M | $26.1M | $27.3M | $19.2M | $17.6M |
| Operating income | -$23.0M | -$51.8M | -$39.0M | -$28.8M | -$24.1M |
| Income tax | — | $66,000 | -$60,000 | -$60,000 | — |
| Net income | -$21.8M | -$44.6M | -$42.8M | -$28.6M | -$24.1M |
| EPS (diluted) | $-8.35 | $-41.89 | $-3.50 | $-4.05 | $-4.35 |
| Operating cash flow | -$23.1M | -$47.6M | -$32.4M | -$25.2M | -$22.6M |
| Free cash flow | -$23.1M | -$47.7M | -$33.2M | -$25.4M | -$22.7M |
| Cash & equivalents | $13.2M | $23.3M | $9.6M | $19.9M | $35.7M |
| Total assets | $15.0M | $25.5M | $12.1M | $21.6M | $37.2M |
| Total liabilities | $5.1M | $9.8M | $25.9M | $6.1M | $4.2M |
| Shareholders' equity | $8.5M | $14.3M | -$15.2M | $8.2M | $33.0M |
Source: SEC EDGAR filings · CIK 0001279704 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.